First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.

What was studied

This was an open-label group in the phase 3 SYMPATICO study. It tested ibrutinib plus venetoclax as a first treatment for mantle cell lymphoma. People were aged 65 or older, with 65 people in that group. Others were adults aged 18 or older with a TP53 gene change, with 11 people. In all, 78 people were enrolled. Both drugs were taken by mouth for 2 years. Ibrutinib alone went on after that.

What they found

People were on the study for a median of 40.5 months. The abstract reports high complete response rates. It also gives the overall response rate. A response lasted a median of 37.1 months. Median progression-free survival was 40.2 months. Median overall survival was not reached. Among people aged 65 or older, those with a TP53 change did less well. Their median progression-free survival was 22.0 months, against 40.2 months without the change. In adults under 65 with a TP53 change, it was 15.4 months. Common side effects were diarrhea, fatigue, neutropenia and COVID-19.

What it means for patients

The authors say the drug pair gave high complete response rates and lasting remissions. They say it may be an option for people aged 65 or older. They say it may also be an option for any age with a TP53 change.

Why it is not certain yet

The abstract describes one open-label group. It names no comparison group. Only 78 people were enrolled. The group of adults with a TP53 change had only 11 people.

Source

First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.

We restate facts from the source record in our own words. The original wording belongs to its publisher.